company background image
CI

CignaNYSE:CI Stock Report

Last Price

US$236.25

Market Cap

US$78.3b

7D

-2.4%

1Y

5.7%

Updated

21 Jan, 2022

Data

Company Financials +
CI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health2/6
Dividends5/6

CI Stock Overview

Cigna Corporation provides insurance and related products and services in the United States.

Cigna Competitors

CVS Health

NYSE:CVS

US$134.2b

DaVita

NYSE:DVA

US$11.1b

Accolade

NasdaqGS:ACCD

US$1.2b

Hims & Hers Health

NYSE:HIMS

US$976.7m

Price History & Performance

Summary of all time highs, changes and price drops for Cigna
Historical stock prices
Current Share PriceUS$236.25
52 Week HighUS$272.81
52 Week LowUS$191.74
Beta0.91
1 Month Change6.26%
3 Month Change9.17%
1 Year Change5.74%
3 Year Change20.36%
5 Year Change60.92%
Change since IPO3,429.05%

Recent News & Updates

Dec 29
At US$231, Is It Time To Put Cigna Corporation (NYSE:CI) On Your Watch List?

At US$231, Is It Time To Put Cigna Corporation (NYSE:CI) On Your Watch List?

Cigna Corporation ( NYSE:CI ) led the NYSE gainers with a relatively large price hike in the past couple of weeks. With...

Dec 19

Cigna: When Quality And Value Meet

Cigna’s third quarter results continue to show strong performance. Management reiterated their long-term goal of achieving 10% to 13% bottom line growth. Selling out of the money cash-secured puts will allow you to essentially have your cake, and eat it too. I rate Cigna a buy below $245.

Dec 05

Cigna's Value Keeps On Growing

Cigna has traded sideways since the Aetna acquisition in late 2018, but it has increased its financial strength substantially since then. Among the benefits flowing to shareholders since the acquisition that are not reflected in a higher stock price are a big dividend increase that may lead to more. Many stocks such as Cigna are out of favor with the market right now, but that may spell opportunity for you if you are a patient income investor.

Shareholder Returns

CIUS HealthcareUS Market
7D-2.4%-3.5%-6.1%
1Y5.7%12.7%4.2%

Return vs Industry: CI underperformed the US Healthcare industry which returned 12.8% over the past year.

Return vs Market: CI matched the US Market which returned 6.6% over the past year.

Price Volatility

Is CI's price volatile compared to industry and market?
CI volatility
CI Average Weekly Movement3.4%
Healthcare Industry Average Movement7.9%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: CI is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: CI's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198172,963David Cordanihttps://www.cigna.com

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company’s U.S.

Cigna Fundamentals Summary

How do Cigna's earnings and revenue compare to its market cap?
CI fundamental statistics
Market CapUS$78.30b
Earnings (TTM)US$8.38b
Revenue (TTM)US$170.40b

9.3x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CI income statement (TTM)
RevenueUS$170.40b
Cost of RevenueUS$147.03b
Gross ProfitUS$23.37b
ExpensesUS$14.98b
EarningsUS$8.38b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 03, 2022

Earnings per share (EPS)25.30
Gross Margin13.71%
Net Profit Margin4.92%
Debt/Equity Ratio72.2%

How did CI perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

12%

Payout Ratio

Valuation

Is Cigna undervalued compared to its fair value and its price relative to the market?

43.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CI ($236.25) is trading below our estimate of fair value ($416.91)

Significantly Below Fair Value: CI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CI is good value based on its PE Ratio (9.3x) compared to the US Healthcare industry average (20.3x).

PE vs Market: CI is good value based on its PE Ratio (9.3x) compared to the US market (16.7x).


Price to Earnings Growth Ratio

PEG Ratio: CI is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: CI is good value based on its PB Ratio (1.7x) compared to the US Healthcare industry average (2.6x).


Future Growth

How is Cigna forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

4.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CI's forecast earnings growth (4.3% per year) is above the savings rate (2%).

Earnings vs Market: CI's earnings (4.3% per year) are forecast to grow slower than the US market (13.1% per year).

High Growth Earnings: CI's earnings are forecast to grow, but not significantly.

Revenue vs Market: CI's revenue (5.4% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: CI's revenue (5.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CI's Return on Equity is forecast to be low in 3 years time (14.6%).


Past Performance

How has Cigna performed over the past 5 years?

33.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CI has a large one-off gain of $3.8B impacting its September 30 2021 financial results.

Growing Profit Margin: CI's current net profit margins (4.9%) are higher than last year (3.4%).


Past Earnings Growth Analysis

Earnings Trend: CI's earnings have grown significantly by 33.5% per year over the past 5 years.

Accelerating Growth: CI's earnings growth over the past year (58.2%) exceeds its 5-year average (33.5% per year).

Earnings vs Industry: CI earnings growth over the past year (58.2%) exceeded the Healthcare industry 32.5%.


Return on Equity

High ROE: CI's Return on Equity (17.7%) is considered low.


Financial Health

How is Cigna's financial position?


Financial Position Analysis

Short Term Liabilities: CI's short term assets ($25.4B) do not cover its short term liabilities ($36.3B).

Long Term Liabilities: CI's short term assets ($25.4B) do not cover its long term liabilities ($70.4B).


Debt to Equity History and Analysis

Debt Level: CI's net debt to equity ratio (62%) is considered high.

Reducing Debt: CI's debt to equity ratio has increased from 36% to 72.2% over the past 5 years.

Debt Coverage: CI's debt is well covered by operating cash flow (21%).

Interest Coverage: CI's interest payments on its debt are well covered by EBIT (6.9x coverage).


Balance Sheet


Dividend

What is Cigna current dividend yield, its reliability and sustainability?

1.69%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CI's dividend (1.69%) is higher than the bottom 25% of dividend payers in the US market (1.36%).

High Dividend: CI's dividend (1.69%) is low compared to the top 25% of dividend payers in the US market (3.55%).


Stability and Growth of Payments

Stable Dividend: CI's dividends per share have been stable in the past 10 years.

Growing Dividend: CI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (12.4%), CI's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CI's dividends in 3 years are forecast to be well covered by earnings (19% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

David Cordani (56 yo)

13.58yrs

Tenure

US$19,929,493

Compensation

Mr. David Michael Cordani serves as Chair of the Board at Cigna Corporation since January 01, 2022. He has been the Chief Executive Officer and President of Cigna Corporation since December 25, 2009 and Ju...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD19.93M) is above average for companies of similar size in the US market ($USD11.42M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CI's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: CI's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cigna Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Cigna Corporation
  • Ticker: CI
  • Exchange: NYSE
  • Founded: 1981
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$78.300b
  • Shares outstanding: 331.43m
  • Website: https://www.cigna.com

Number of Employees


Location

  • Cigna Corporation
  • Wilde Building
  • 900 Cottage Grove Road
  • Bloomfield
  • Connecticut
  • 6002
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:35
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.